File No. 230686

Committee Item No.4Board Item No.2

COMMITTEE/BOARD OF SUPERVISORS

AGENDA PACKET CONTENTS LIST

Committee: <u>Government Audit and Oversight</u> **Board of Supervisors Meeting:**

 Date:
 July 20, 2023

 Date:
 September 12, 2023

Cmte Board

		Motion Resolution
\boxtimes	\square	Ordinance
		Legislative Digest
		Budget and Legislative Analyst Report
		Youth Commission Report
		Introduction Form
		Department/Agency Cover Letter and/or Report
		MOU - FY2022-2024 - Clean
		MOU - FY2022-2024 - Redline
		Grant Information Form
		Grant Budget
		Subcontract Budget
		Contract / DRAFT Mills Act Agreement
		Form 126 – Ethics Commission
		Award Letter
		Application
		Public Correspondence

OTHER

Prepared by:	Stephanie Cabrera	Date:	July 12, 2023
Prepared by:	Stephanie Cabrera	Date:	July 25, 2023
Prepared by:	-	_ Date:	

FILE NO. 230686

ORDINANCE NO.

,	1	

2 Ordinance authorizing settlement of the lawsuit filed by the City and County of San 3 Francisco and the People of the State of California against Walgreen Co. for 4 \$229,610,002 (the City to be paid \$200,000,002 over 15 years, the City's outside counsel 5 to be paid \$29,610,000); the lawsuit was filed on December 18, 2018, in the United 6 7 States District Court for the Northern District of California, Case No. 3:18-cv-7591-CRB-JSC; entitled The City and County of San Francisco and the People of the State of 8 California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer 9 D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa 10 11 Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler 12 Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International PIc, Endo Health Solutions 13 Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, 14 Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc f/k/a Actavis Plc, Watson 15 Pharmaceuticals, Inc. n/k/a Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, 16 17 Actavis Pharma, Inc. f/k/a Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; the lawsuit involves Walgreen Co.'s 18 improper and unlawful dispensing of prescription opioids at its pharmacies, which 19 contributed to the epidemic of opioid abuse and misuse and caused a public nuisance 20 in San Francisco. 21 22 Be it ordained by the People of the City and County of San Francisco: 23 24 Section 1. Pursuant to Charter Section 6.102(5), the Board of Supervisors hereby authorizes the City Attorney to settle the action entitled The City and County of San Francisco 25

[Settlement of Lawsuit - Walgreen Co. - City to Receive \$229,610,002 Over 15 Years]

1 and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, 2 3 Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler 4 Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., 5 Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo 6 Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt 7 Plc, Mallinckrodt LLC, Allergan Plc f/k/a Actavis Plc, Watson Pharmaceuticals, Inc. n/k/a 8 Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. f/k/a Watson 9 Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson 10 Corporation, the United States District Court for the Northern District of California, Case No. 11 3:18-cv-7591-CRB-JSC by the payment of \$229,610,002 (the City to be paid \$200,000,002 12 over 15 years, the City's outside counsel to be paid \$29,610,000) by Walgreen Co. The 13 lawsuit involves Walgreen Co.'s improper and unlawful dispensing of prescription opioids at its 14 pharmacies, which contributed to the epidemic of opioid abuse and misuse and caused a public nuisance in San Francisco. 15

Section 2. The above-named action was filed in the United States District Court for the 16 Northern District of California on December 18, 2018, and the following parties were named in 17 18 the lawsuit: The City and County of San Francisco and the People of the State of California, as plaintiffs; Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company, Inc.; 19 Rhodes Pharmaceuticals L.P.; Richard S. Sackler; Jonathan D. Sackler; Mortimer D.A. 20 21 Sackler, Kathe A. Sackler; Ilene Sackler Lefcourt; Beverly Sackler; Theresa Sackler; David A. Sackler; Trust for the Benefit of the Raymond Sackler Family; Allergan Plc f/k/a Actavis Plc; 22 23 Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc.; Allergan Sales, 24 LLC; Allergan USA, Inc.; Watson Laboratories, Inc.; Warner Chilcott Company, LLC; Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.; Actavis South Atlantic LLC; Actavis Elizabeth LLC; 25

City Attorney BOARD OF SUPERVISORS

1	Actavis Mid Atlantic LLC; Actavis Totowa LLC; Actavis LLC; Actavis Kadian LLC; Actavis					
2	Laboratories UT, Inc. f/k/a Watson Laboratories, IncSalt Lake City; Actavis Laboratories FL,					
3	Inc. f/k/a Watson Laboratories, IncFlorida; Teva Pharmaceuticals USA, Inc.; Teva					
4	Pharmaceutical Industries Ltd.; Cephalon, Inc.; Johnson & Johnson; Janssen					
5	Pharmaceuticals, Inc.; Noramco, Inc.; Ortho-Mcneil-Janssen Pharmaceuticals, Inc.; Janssen					
6	Pharmaceutica, Inc.; Endo Health Solutions Inc.; Endo Pharmaceuticals, Inc.; Par					
7	Pharmaceuticals, Inc.; Par Pharmaceutical Companies, Inc. f/k/a Par Pharmaceutical					
8	Holdings, Inc.; Endo International Plc; Insys Therapeutics, Inc.; Mallinckrodt Plc; Mallinckrodt					
9	LLC; Specgx LLC; AmerisourceBergen Drug Corporation; Anda, Inc.; Cardinal Health, Inc.;					
10	McKesson Corporation; and Walgreen Co. as defendants.					
11						
12						
13	APPROVED AS TO FORM: DAVID CHIU, City Attorney					
14						
15	By: <u>/s/ Sara J. Eisenberg</u> SARA J. EISENBERG					
16	Chief of Complex and Affirmative Litigation					
17	n:\cpu\li2023\190034\01678005.docx					
18						
19						
20						
21						
22						
23						
24						
25						